At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Niki Karachaliou, MD, from…
La Dra Enriqueta Felip explica las principales cuestiones que se han tratado en el 6º Congreso Europeo de Cáncer de…
Professor Joseph Mikhael, MD from Mayo Clinic, Scottsdale, AZ talks to us about the use of social media during medical…
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg…
Eric Klein, MD from the Glickman Urology & Kidney Institute, Cleveland, OH discusses biopsy-based genomic testing in men with early-stage…
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, David Carbone, MD, PhD,…
David Steensma, MD of the Dana-Faber Cancer Institute, Boston, MA discusses the arrival of a new splicing modulator called H3B-8800…
Sahra Ali, MD from Queen’s Centre Castle Hill Hospital, Hull, UK discusses the need to set up a registry for…
David Steensma, MD of the Dana-Faber Cancer Institute, Boston, MA discusses the recurrent mutation in patients with myelodysplastic syndromes (MDS).…
Sonja Zweegman, MD, PhD from the VU University Medical Center, Amsterdam, Netherlands gives an overview of her talk on risk…
Sahra Ali, MD from Queen’s Centre Castle Hill Hospital, Hull, UK gives an overivew of acute myeloid leukemia (AML) in…
Peter Dreger, MD from Heidelberg University Hospital, Heidelberg, Germany gives an overview of his talk on the current role of…
David Steensma, MD of the Dana-Faber Cancer Institute, Boston, MA gives an overview of his talk on how to treat…
Chng Wee Joo, MB, ChB, PhD, FRCP, FRCPath, FAMS from the National University Cancer Institute, Singapore discusses how next-generation sequencing…
Mark Caulfield, MD from Genomics England and Queen Mary University, London, UK gives an overview of the 100,000 Genomes Project,…
Gail Roboz, MD from Weill Medical College of Cornell University, New York, NY gives an overview of her talk on…
David Steensma, MD of the Dana-Faber Cancer institute, Boston, MA gives an overview of his talk on precision medicine for…
Chng Wee Joo, MB, ChB, PhD, FRCP, FRCPath, FAMS from the National University Cancer Institute, Singapore gives an overview of…
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg…
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg…
This Expert Perspectives activity features the clinical faculty from a symposium held at the 2016 Annual Meeting of the Oncology…
In this presentation from the “CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer – Advancing Nursing Care to Improve…
In this presentation from the “CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer – Advancing Nursing Care to Improve…
In this presentation from the “CDK 4/6 Inhibitor Therapy for ER+ Metastatic Breast Cancer – Advancing Nursing Care to Improve…
Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, and President of the European Society for Blood and Marrow Transplantation…
At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), held in Valencia, Spain, John…
Chiara Bonini, MD, from San Raffaele Scientific Institute, Milan, Italy, gives an overview of the ongoing randomised Phase III trial…
Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain discusses open questions in the assessment of response in multiple…
Bruno Paiva, PhD, from the University of Navarra, Pamplona, Spain discusses the current status of novel treatments in multiple myleoma…
Arnon Nagler, MD, from Sheba Medical Center, Tel Hashomer, Israel, discusses why immunotherapy is his highlight from the 2016 Annual…
Ali Bazarbachi, MD, from the American University of Beirut, Beirut, Lebanon explains his research into the use of FLT3 inhibitors…
Arnon Nagler, MD, from Sheba Medical Center, Tel Hashomer, Israel, discusses the use of drugs and transplantation in acute leukemias.…
Ann Leen, PhD, from Baylor College of Medicine, Houston, TX, US, provides an overview of the safety and effectivness of…
Ali Bazarbachi, MD, from the American University of Beirut, Beirut, Lebanon provides an overview of FLT3 mutations in acute myeloid…
Ivan Borello, MD from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Batlimore, MD discusses the highlights in immunotherapy and…
Stephen Russell, MD, PhD from the Mayo Clinic, Rochester, MN discusses highlights from the session ‘Environment biology insights’ in multiple…
Philippe Moreau, MD from the University Hospital of Nantes, Nantes, France gives an overview of the Cassiopeia trial on daratumumab…
Paul Richardson, MD from the Dana-Farber Cancer Institute, Boston, MA discusses his talk on ‘Perspectives on future paths to cure’…
Ola Landgren, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, NY gives an overview of his talk…
Nikhil Munshi, MD from the Dana-Farber Cancer Institute, Boston, MA gives an overview of the data presented on the Dana-Farber…
At the Myeloma 2016 meeting held in Boston, MA, Daniel Auclair, PhD, from the Multiple Myeloma Research foundation (MMRF) discusses…
Lawrence Boise, PhD, from the Winship Cancer Institute, Atlanta, GA, discusses the mechanism of action of venetoclax and next steps…
Jesús San Miguel, MD, PhD, from the University of Navarra, Navarra, Spain gives an overview of his talk on ‘Immunotherapy…
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium gives an overview of the mechanism of action of…
Carlos Fernandez de Larrea, MD, PhD from the Hospital ClÃnic de Barcelona, Barcelona, Spain discusses the definition of complete remission…
MarÃa-Victoria Mateos, MD, PhD, from the University Hospital of Salamanca, Salamanca, Spain gives an overview of the challenges associated with…
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium gives an overview of the two trials on second…
Thierry Facon, MD, PhD, from Hospital Claude Huriez, Lille, France provides an overview of the topics and sessions covered at…
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium discusses the role of bortezomib in relapsed/refractroy multiple myeloma…
Sagar Lonial, MD, from Emory University Winship Cancer Institute, Atlanta, GA, USA provides an overview of monoclonal antibodies and checkpoint…
Paula RodrÃguez, MD, PhD from the University Clinic of Navarra, Pamplona, Spain gives an overview of her talk on anticancer…
Hervé Avet-Loiseau, MD, PhD from the Cancer Research Center of Toulouse, Toulouse, France talks about the progress that has been…
Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France gives an overview of his talk on the access to…
Hervé Avet-Loiseau, MD, PhD from the Cancer Research Center of Toulouse, Toulouse, France discusses the impact of next-generation sequencing (NGS)…
Evangelos Terpos, MD, PhD, University of Athens, Athens, Greece discusses the open issues in the use of imaging techniques for…
Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France discusses the role of the patient in the debate around…
Evangelos Terpos, MD, PhD, from the University of Athens, Athens, Greece discusses the limitations and challenges associated with using various…
Antonio Palumbo, MD, from the University of Turin, Turin, Italy provides an overview of the diagnostic criteria for smouldering myeloma.…
Carlos Fernandez de Larrea, MD, PhD from the Hospital ClÃnic de Barcelona, Barcelona, Spain discusses which techniques can be used…
Antonio Palumbo, MD, from the University of Turin, Turin, Italy provides treatment advice for smouldering myeloma. The key message, according…
Antonio Palumbo, MD, from the University of Turin, Turin, Italy provides advice on how to treat multiple myeloma (MM). For…
In this introductory video on head and neck cancer, radiation oncologist Dr. Carryn Anderson of the University of Iowa defines…
Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France and Arnon Nagler, MD, from the Sheba Medical Center, Tel Hashomer,…
Jesús San Miguel, MD, PhD, from the University of Navarra, Navarra, Spain gives an overview of immunomodulatory drugs (IMiDs) thalidomide,…
Philippe Moreau, MD from the University Hospital of Nantes, Nantes, France gives an overview of a prospective comparison on PET-CT…
Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France gives two message to stakeholders, such as pharmaceutical companies, the…
Paula RodrÃguez, MD, PhD from the University Clinic of Navarra, Pamplona, Spain gives an overview of the two main PD-1…
Michel Delforge, MD, PhD from the University Hospital Leuven, Leuven, Belgium provides an overview of the approval of proteasome inhibitors…
Hervé Avet-Loiseau, MD, PhD from the Cancer Research Center of Toulouse, Toulouse, France discusses his talk on prognostic factors in…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Alessandro M. Vannucchi discusses the…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Nicolaus Kröger discusses the influence…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Mary F. McMulllin discusses how…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Srdan Verstovsek provides an update…
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA,…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Theo De Witte discusses novel…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Michael Pfeilstöcker discusses newer therapeutic…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Martin Jädersten provides an update…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Fabio Efficace discusses quality of…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Torsten Haferlach discusses whether mutational…
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA,…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Gunnar BirgegÃ¥rd discusses what we…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Jean-Jacques Kiladjian provides and update…
In this presentation from the 2016 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 26-27 in Alexandria, VA,…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Tiziano Barbui discusses the updated…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Rajko Kuec discusses the interplay…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Marie-Caterine Le Bousse-Kerdilès discusses cytokines,…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Mario Cazzola discusses somatic mutations…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Carol Gambacorti-Passerini discusses the genetic…
In this presentation from the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes”, Dr. Eric Solary discusses the genetic…
This discussion between the chairs of the 2016 “European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes” provides a summary of…
In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Alessandro M. Vannucchi argues that early-stage…
In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Paola Guglielmelli discusses the clinical benefit…
In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Franscisco Cervantes discusses emerging JAK2 inhibitor…
In this presentation from the “MPN Therapies: Emerging Concepts for Enhanced Outcomes” symposium, Dr. Mario Cazzola argues that early-stage myelofibrosis…
Metastatic Colorectal Cancer” symposium, Eric Van Cutsem discusses the emerging treatment options for metastatic colorectal cancer patients in the late-line…
In this presentation from the “Individualizing Late-Line Treatment for Patients with Metastatic Colorectal Cancer” symposium, Dr. Howard S. Hochster discusses…
This discussion presents a discussion between world-renowned thought leaders Axel Grothey, Howard Hochster, and Eric Van Cutsem, who elucidate the…
In this webcast, Dr. David P. Steensma discusses the most pertinent information presented on leukemia and myeloid disorders during the…
In this webcast, Dr. John P. Leonard discusses the most pertinent information presented on lymphoma during the 2016 Great Debates…
In this webcast, Dr. Robert Z. Orlowski discusses the most pertinent information presented on multiple myeloma during the 2016 Great…
Advancements in breast cancer care continue to rapidly evolve and the San Antonio Breast Cancer Symposium (SABCS) is the premier…
Polycythemia vera (PV) is characterized by erythrocytosis, thrombocytosis, and/or leukocytosis with a broad-range of disease-related symptoms that impact the overall…
Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen…
Cyclin-dependent kinase (CDK) 4/6 inhibitors in combination with antiestrogen therapy work to combat endocrine resistance in women with estrogen ER+…
The cyclin-dependent kinase (CDK) pathway is critical to cell cycle entry. In many tumor types, including breast cancer, there is…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Paul Baas discusses updates in the systemic…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Elisabeth Quoix discusses the optimatl treatment of…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Maurice Perol discusses the targeting of angiogenesis…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Pieter E. Postmus discusses the maintenance paradigm…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Lucio Crino? discusses the first- and second-generation…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Rafal Dziadziuszko discusses strategies for overcoming KRAS…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Lucio Crino? discusses extreme rare mutations in…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Nicholas Girard discusses the mechanisms of resistance…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Guilio Rossi discusses the an algorithm for…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. John Gosney discusses the inherent challenges faced…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Joachim G. Aerts discusses response criteria and…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Joachim G. Aerts discusses how biomarkers predict…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. David Waller argues that surgery is the…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Umberto Ricardi argues that steretactic body radiation…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. John Vansteenkiste discusses the current status of…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Richard Booton discusses the use of endobronchial…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Pieter E. Postmus discusses new proposals for…
In this presentation from the “17th Annual Congress: Perspectives in Lung Cancer”, Dr. Klaus Irion discusses the use of diagnotics…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. John P. Leonard argues that watch and…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Michael E. Williams argues that “watch and…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Andrew M. Evens discusses the latest in…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Morton Coleman argues that one should not…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Michell R. Smith argues that we should…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Tracy Batchelor discusses the latest updates in…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jonathan Friedberg argues that young paitnts with…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Brad S. Kahl argues that young patients…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Anas Younas discusses immune checkpoint inhibitors in…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Richard I. Fisher argues that R-CHOP should…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Pierluigi Porcu argues that allogeneic stem cell…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Rafael Bejar discusses the promises and pitfalls…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Selina M. Luger argues that hypomethylating agents…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Eric Padron discusses the management of chronic…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben A. Mesa discusses combination therapy with…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Sarah Nikiforow discusses the diagnosis and management…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Kenneth A. Bauer discusses the reversal of…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Eric Padron discusses the diagnosis and management…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jerald P. Racdich discusses practical advices for…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jerald P. Radich discusses at what point…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul Barr argues that the optimal treatment…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Jacqueline Barrientos argues that ibrutinib is the…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Timothy Call discusses the clinical considerations for…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Richard R. Furman argues that CR and…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Robert Z. Orlowski argues that the best…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that the best…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that upfront transplant…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben Niesvizky argues that high risk myeloma…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Robert Z. Orlowski argues that high risk…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Paul G. Richardson argues that the standard…
In this presentation from “Great Debates and Updates in Hematologic Malignancies 2016”, Dr. Ruben Niesvizky discusses the use of monoclonal…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Josep Tabernero discusses novel approaches to trial…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Karen T. Brown argues that ablation is…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael A. Choti argues that the optimal…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that FOLFIRINOX is…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that FOLFIRINOX is…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael A. Choti argues that chemotherapy alone…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Jeffrey A. Meyerhardt argues that epirubicin and…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. David H. Ilson argues that epirubicin and…
A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex,…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that the optimal…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Josep Tabernero discusses the molecular subtyping/profiling of…
In this presentation from “Great Debates and Updates in GI Malignancies 2016” Dr. James C. Yao argues that bevacizumab cannot…
A continuing education program is offered as a supplement to this webcast at the following location: http://elc.imedex.com/ELC/Activity-Search.aspx?search=7205 © 2016 Imedex,…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Diane Reidy-Lagunes argues that everolimus does not…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. James C. Yao argues that everolimus has…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Mark Andrew Dickson discusses the management of…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Michael J. Hall discusses genetics in gastrointestinal…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Luis A. Diaz discusses the use of…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Christopher H. Lieu discusses novel therapies for…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Howard S. Hochster argues that biomarkers beyond…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Jeffrey A. Meyerhardt discusses inflammation in colorectal…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that TAS-102 followed by…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Eric Van Cutsem argues that the preferred…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Andrea Cercek argues that borderline-resectable liver metastasis…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that borderline-resectable liver metastasis…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Tanios Bekaii-Saab argues that radioembolization of colorectal…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Eric Van Cutsem argues that radioembolization of…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Tanios Bekaii-Saab argues that there is no…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Andrea Cercek argues that there is an…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Axel Grothey argues that biomarkers do not…
In this presentation from “Great Debates and Updates in GI Malignancies 2016”, Dr. Christopher H. Lieu discusses the use of…
In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Charles B. Simone examines novel forms of radation…
In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Harvey I. Pass arguest that a trimodality approach…
In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Mark A. Socinski proposes that a bimodality approarch…
In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Mark A. Socinski discusses whether or not the…
In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. Harvey I. Pass discusses the mangement of the…
In this presentatino, Dr. Gerard A. Silvestri outlines his perspective on the updated TNM classifications for malignant tumors, and expounds…
In this presentation from the “20th Annual Perspectives in Thoracic Oncology” Dr. Laura Jean Bierut examines current strategies for curtailing…
In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Benjamin Levy queries whether liquid biopsy will replace…
In this presentation from the “20th Annual Perspectives in Thoracic Oncology”, Dr. William K. Evans discusses the current cost and…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Sven de Vos disuccese new…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jonathan Friedberg argues against the…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Gilles Salles argues that maintenance…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Thomas E. Witzig discusses how…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jia Ruan examines the best…
In this presenation, Dr. Kami Maddocks discusses who should get what for upfront therapy of mantle cell lymphoma (MCL). A…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Adam M. Petrich discusses the…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. John P. Leonard discusses the…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Laurie H. Sehn discusses the…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Randy Gascoyne discusses the future…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jonathan Friedberg discusses the highlights…
In this abstract presentation, Dr. Steve Coutre discusses the use of 420 mg of single-agent ibrutinib to induce durable responses…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Steve M. Ansell discusses the…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Koen van Besien argues that…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies” Dr. Robert W. Chen argues that…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jeremy Abramson argues that chemotherapy-based…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Allison Moskowitz argues that single-agent…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Giorgio Inghirami discusses whether or…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Irene M. Ghobrial discusses why…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Esteban Braggio discusses how useful…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Koen van Besien disccusses patient…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. John Allan discusses the risks,…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jennifer R. Brown discusses whether…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Richard R. Furman elucidates the…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Mitchell R. Smith discusses when…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Steve Coutre discusses tyrosine-kinase inhibitors…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Richard R. Furman discusses risk…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Kanti Rai discuses the most…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Neil Kay discusses the targeted…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Kenneth C. Anderson discusses new…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Guentehr Koehne examines whether there…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Sundar Jagannath argues against maintenance…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Antonio Palumbo argues in favor…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. James R. Berenson argues that…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Tomer Mark argues that it…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Ajai Chari argues that it…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Antonio Palumbo discusses the best…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. David Roodman discusses the advances…
In this abstract presentation, Dr. Paul G. Richardson discusses the results of a mutlicenter Phase 2 trial on the use…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Renier J. Brentjens discusses the…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Jatin J. Shah discusses whether…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. C. Ola Landgren examines whether…
In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. James R. Berenson discusses B-cell…
Carlos Fernandez de Larrea, MD, PhD from the Hospital ClÃnic de Barcelona, Barcelona, Spain gives an overview of his talk…
Do I need head and neck specialists for my cancer? Patient Power Founder and Host, Andrew Schorr, discusses this question…
What are the targeted and less toxic treatments for head and neck cancers? Patient Power Founder and Host, Andrew Schorr,…
What exactly is MRD? Who should be tested? From the Myeloma 2016 meeting in Boston, Dr. Ola Landgren from Memorial…
How much of a difference in counts can you expect to see if you have blood drawn and processed at…
Is stem cell transplant a viable treatment option? How long should maintenance therapy last? From the Myeloma 2016 meeting in…
Patient Power Founder and Host, Andrew Schorr, discusses cancer screening with MD Anderson Cancer Centers Head and Neck Surgeon and…
How do I manage my cancer pain? Patient Power Founder and Host, Andrew Schorr, interviews MD Anderson Cancer Center’s pain…
At the 2016 World Congress of the International Society of Hematology (ISH) held in Glasgow, Scotland, Paul Richardson, MD, from…
At the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in…
What causes lung cancer? Can it be passed on genetically? Lung cancer experts Dr. George Simon of MD Anderson Cancer…
In this Ask the Expert segment, Patient Power community member, Peggy, wrote, How strong of a connection is there between…
As part of Patient Powers coverage of Myeloma 2016, several renowned multiple myeloma experts joined together to discuss what they…